Scarica l'app Stockscreener
149.86
0.77%
-1.17
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$151.03
Aprire:
$153.06
Volume 24 ore:
2.37M
Relative Volume:
0.80
Capitalizzazione di mercato:
$31.96B
Reddito:
$447.02M
Utile/perdita netta:
$-1.18B
Rapporto P/E:
-24.24
EPS:
-6.1812
Flusso di cassa netto:
$-906.14M
1 W Prestazione:
-4.47%
1M Prestazione:
-14.40%
6M Prestazione:
+34.69%
1 anno Prestazione:
+85.52%
Intervallo 1D:
$149.34
$155.79
Intervallo di 1 settimana:
$149.34
$158.98
Portata 52W:
$60.40
$212.75
Insmed Inc Stock (INSM) Company Profile
Nome
Insmed Inc
Settore
Industria
Telefono
908-977-9900
Indirizzo
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Compare INSM vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
149.86 | 32.21B | 447.02M | -1.18B | -906.14M | -6.1812 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.92 | 116.41B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
785.51 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
811.45 | 50.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.76B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
353.92 | 38.40B | 4.98B | 69.60M | 525.67M | 0.5198 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-28 | Iniziato | Barclays | Overweight |
| 2026-01-23 | Iniziato | Roth Capital | Buy |
| 2025-12-19 | Ripresa | Truist | Buy |
| 2025-12-04 | Iniziato | Rothschild & Co Redburn | Buy |
| 2025-10-28 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-10-20 | Iniziato | Wells Fargo | Overweight |
| 2025-08-20 | Iniziato | William Blair | Outperform |
| 2025-08-13 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | Iniziato | Jefferies | Buy |
| 2025-02-25 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-04-23 | Iniziato | Truist | Buy |
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2023-11-20 | Ripresa | JP Morgan | Overweight |
| 2023-07-26 | Iniziato | Guggenheim | Buy |
| 2022-12-09 | Iniziato | Mizuho | Buy |
| 2022-12-07 | Iniziato | Barclays | Overweight |
| 2022-11-18 | Iniziato | BofA Securities | Buy |
| 2022-04-27 | Iniziato | Goldman | Buy |
| 2021-12-06 | Iniziato | JP Morgan | Overweight |
| 2021-10-19 | Ripresa | Monness Crespi & Hardt | Buy |
| 2021-10-19 | Ripresa | Morgan Stanley | Overweight |
| 2021-10-08 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2020-12-17 | Iniziato | Berenberg | Buy |
| 2020-10-12 | Ripresa | Stifel | Buy |
| 2019-09-03 | Iniziato | Goldman | Buy |
| 2019-04-09 | Reiterato | H.C. Wainwright | Buy |
| 2019-02-15 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-01-17 | Aggiornamento | Goldman | Neutral → Buy |
| 2019-01-02 | Iniziato | Canaccord Genuity | Buy |
| 2018-08-06 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-07-23 | Iniziato | Goldman | Neutral |
| 2018-04-23 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2018-03-21 | Iniziato | Morgan Stanley | Overweight |
| 2018-01-18 | Iniziato | Credit Suisse | Neutral |
| 2017-09-05 | Reiterato | Evercore ISI | Outperform |
| 2017-08-17 | Iniziato | Evercore ISI | Outperform |
| 2017-07-11 | Iniziato | Robert W. Baird | Outperform |
| 2016-03-15 | Iniziato | Stifel | Buy |
| 2015-11-09 | Downgrade | UBS | Buy → Neutral |
| 2015-10-06 | Reiterato | H.C. Wainwright | Buy |
| 2015-06-09 | Iniziato | Citigroup | Neutral |
| 2014-03-26 | Reiterato | HC Wainwright | Buy |
Mostra tutto
Insmed Inc Borsa (INSM) Ultime notizie
Insider Sell: Martina Flammer Sells Shares of Insmed Inc (INSM) - GuruFocus
Valuation Update: Is Insmed Incorporated stock a buy or sell2025 Market Outlook & Verified High Yield Trade Plans - baoquankhu1.vn
Insmed to Host Fourth-Quarter and Full-Year 2025 Financial Results Conference Call on Thursday, February 19, 2026 - Yahoo Finance
Truist Financial Corp Sells 7,420 Shares of Insmed, Inc. $INSM - MarketBeat
Insmed, Inc. $INSM Stock Holdings Lessened by WCM Investment Management LLC - MarketBeat
Insmed Presents Data on TPIP Inhalation Drug for PAH - respiratory-therapy.com
MACD Signal: What are the risks of holding Insmed Incorporated2025 Retail Activity & Step-by-Step Swing Trade Plans - baoquankhu1.vn
Principal Financial Group Inc. Has $124.47 Million Holdings in Insmed, Inc. $INSM - MarketBeat
Whale Trades: What are the risks of holding Insmed IncorporatedMarket Movement Recap & Capital Efficiency Focused Strategies - baoquankhu1.vn
Y Intercept Hong Kong Ltd Decreases Position in Insmed, Inc. $INSM - MarketBeat
Rate Cut: Will Insmed Incorporated outperform its industry peers2025 Trading Volume Trends & Low Drawdown Trading Techniques - baoquankhu1.vn
Bank of New York Mellon Corp Trims Stock Holdings in Insmed, Inc. $INSM - MarketBeat
Insmed (INSM) Sees Surge in Bullish Option Activity - GuruFocus
Morgan Stanley Updates Rating for Insmed (INSM), Adjusts Price T - GuruFocus
New York State Common Retirement Fund Buys 18,123 Shares of Insmed, Inc. $INSM - MarketBeat
What Insmed (INSM)'s Upcoming TPIP Data and New Analyst Coverage Mean For Shareholders - Yahoo Finance
Insmed TPIP Data At PVRI 2026 Tests Pulmonary Arterial Hypertension Ambitions - Yahoo Finance
Insmed (NASDAQ:INSM) Coverage Initiated at Barclays - MarketBeat
Definium Therapeutics Appoints Roger Adsett To Board - citybiz
Definium Therapeutics Appoints Roger Adsett to Board of Directors, Effective from January 29, 2025 - marketscreener.com
J. Safra Sarasin Holding AG Invests $1.09 Million in Insmed, Inc. $INSM - MarketBeat
Definium Therapeutics Appoints Roger Adsett to Board of Directors - Business Wire
Pulmonary Arterial Hypertension Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Ribomic, Gmax Biopharm, Novartis, Cereno Scientific AB, Insmed - Barchart.com
Barclays Initiates Coverage on Insmed With Overweight Rating, $231 Price Target - marketscreener.com
Barclays Initiates Coverage on Insmed (INSM) with Overweight Rat - GuruFocus
Insmed to Present Multiple Abstracts on Treprostinil Palmitil Inhalation Powder (TPIP) at Pulmonary Vascular Research Institute (PVRI) 2026 Congress - PR Newswire
EFG Asset Management North America Corp. Reduces Stake in Insmed, Inc. $INSM - MarketBeat
New Phase 3 PAH trial design, imaging data put TPIP in PVRI 2026 spotlight - stocktitan.net
Mutual of America Capital Management LLC Lowers Stock Holdings in Insmed, Inc. $INSM - MarketBeat
Strs Ohio Grows Stake in Insmed, Inc. $INSM - MarketBeat
Does Insmed Incorporated have strong fundamentalsJuly 2025 News Drivers & AI Based Buy and Sell Signals - baoquankhu1.vn
Universal Beteiligungs und Servicegesellschaft mbH Trims Stake in Insmed, Inc. $INSM - MarketBeat
Insmed Incorporated (INSM) Stock Analysis: Potential 37% Upside Amid Robust Revenue Growth - DirectorsTalk Interviews
Setup Watch: What is ROIVs book value per shareWall Street Watch & Risk Adjusted Buy and Sell Alerts - baoquankhu1.vn
Insmed, Inc. $INSM Stock Holdings Lessened by Emerald Mutual Fund Advisers Trust - MarketBeat
Roth Capital Initiates Coverage of Insmed (INSM) with Buy Recommendation - Nasdaq
Stifel Initiates Insmed(INSM.US) With Buy Rating, Announces Target Price $212 - 富途资讯
Roth Capital Initiates Coverage on Insmed (INSM) with Buy Rating - GuruFocus
Roth/MKM initiates Insmed stock with Buy rating, $212 price target - Investing.com Canada
Insmed (INSM) chair and CEO Lewis sells $1.7M in stock By Investing.com - Investing.com Nigeria
Insmed (INSM) chair and CEO Lewis sells $1.7M in stock - Investing.com
Insider Selling: Insmed (NASDAQ:INSM) CEO Sells 10,699 Shares of Stock - MarketBeat
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed IncorporatedINSM - PR Newswire
Breaking Down Insmed: 18 Analysts Share Their Views - Benzinga
Insmed stock price target raised to $200 by RBC on Brinsupri success - Investing.com Canada
RBC Capital Raises Price Target for Insmed (INSM) to $200 | INSM Stock News - GuruFocus
Analyst weighs patent cliff risks against Insmed’s (INSM) growth story - MSN
What are the risks of holding Insmed IncorporatedTrade Ideas & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
Market Review: Is Insmed Incorporated stock a smart retirement pick2025 Performance Recap & Consistent Growth Equity Picks - baoquankhu1.vn
Insmed Inc (INSM US): Brinsupri on High Trajectory; Multiple Readouts to Make 2026 a Pivotal Year - Smartkarma
Aug Reactions: Does Capital Growth Mortgage Investors L P Preferred Security have strong EBITDA marginsPortfolio Return Summary & High Conviction Buy Zone Alerts - baoquankhu1.vn
Insmed Inc Azioni (INSM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.02%
0.93%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):